Consensus estimates for Q1 2026 anticipate Telix will report revenue of $230 million and an EPS of -$0.01, while the current stock price of $13.60 trades significantly below the average analyst price target of $23.32.
Investors are primarily focused on the growth of the company's 'Precision Medicine' segment, which encompasses sales of its flagship Illuccix imaging kit and the newly approved Gozellix. This revenue stream increased 11% sequentially in the first quarter, driven by a 5% expansion in U.S. dose volumes and improved market share. Markets are also monitoring progress in the therapeutic pipeline, specifically the ProstACT Global Phase 3 study and upcoming regulatory decision dates for the brain-cancer imaging agent Pixclara.